AIGH Capital Management LLC Buys 872,303 Shares of RenovoRx, Inc. $RNXT

AIGH Capital Management LLC boosted its stake in shares of RenovoRx, Inc. (NASDAQ:RNXT) by 30.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 3,706,197 shares of the company’s stock after buying an additional 872,303 shares during the period. RenovoRx makes up approximately 0.5% of AIGH Capital Management LLC’s holdings, making the stock its 28th largest holding. AIGH Capital Management LLC owned approximately 8.23% of RenovoRx worth $3,682,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. XTX Topco Ltd boosted its stake in RenovoRx by 58.6% during the fourth quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after buying an additional 18,525 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of RenovoRx in the 2nd quarter worth about $98,000. Citadel Advisors LLC bought a new stake in shares of RenovoRx in the 3rd quarter worth about $154,000. Wealthspire Advisors LLC purchased a new position in shares of RenovoRx during the 4th quarter worth about $212,000. Finally, Geode Capital Management LLC boosted its stake in shares of RenovoRx by 9.9% during the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after purchasing an additional 31,730 shares during the period. 3.10% of the stock is currently owned by institutional investors.

RenovoRx Price Performance

RNXT stock opened at $0.90 on Thursday. RenovoRx, Inc. has a 12 month low of $0.70 and a 12 month high of $1.45. The firm’s 50-day moving average is $0.89 and its 200 day moving average is $0.93. The company has a market capitalization of $40.55 million, a PE ratio of -2.73 and a beta of 0.99.

RenovoRx (NASDAQ:RNXT) last issued its earnings results on Thursday, May 14th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.47 million. RenovoRx had a negative net margin of 823.98% and a negative return on equity of 135.03%. Sell-side analysts forecast that RenovoRx, Inc. will post -0.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RNXT has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of RenovoRx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Ascendiant Capital Markets boosted their target price on RenovoRx from $13.50 to $14.00 and gave the company a “buy” rating in a research report on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of RenovoRx in a research note on Wednesday, April 8th. Finally, Wall Street Zen cut RenovoRx from a “hold” rating to a “strong sell” rating in a research note on Saturday, April 4th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, RenovoRx currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.